,text,position,name,last,events,dateString,collapsed,checked
0,"<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",0,Application Received,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Apr 2023', 'fs': 'Apr 2023', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000004CpcL2AS'}, 'Id': 'a0POZ000004CpcL2AS', 'Event_Date__c': '2023-04-13', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Formatted_Date__c': 'Apr 2023', 'Status_History__c': 'a132P000000EDk6QAG'}, 'change': None}]",Apr 2023,False,True
1,"<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/"" rel=""nofollow"">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/"" rel=""nofollow"">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>
<p style=""height: 20px"">&nbsp;</p>
<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>
<p style=""height: 15px"">&nbsp;</p>
<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>
<p style=""height: 20px"">&nbsp;</p>
<p><a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/"" rel=""nofollow"">PTAC</a>  and <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//"" rel=""nofollow"">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",1,Seeking Clinical Advice,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2023', 'fs': 'May 2023', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000004CpcM2AS'}, 'Id': 'a0POZ000004CpcM2AS', 'Event_Date__c': '2023-05-03', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'May 2023', 'Status_History__c': 'a132P000000EDpwQAG'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jul 2023', 'fs': 'Jul 2023', 'change': None}, 'Event_Description': {'s': 'Assigned to Pharmacology and Therapeutics Advisory Committee (PTAC) meeting to provide advice on Friday 18 August 2023', 'fs': 'Assigned to Pharmacology and Therapeutics Advisory Committee (PTAC) meeting to provide advice on Friday 18 August 2023', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000004CpcN2AS'}, 'Id': 'a0POZ000004CpcN2AS', 'Event_Date__c': '2023-07-31', 'Event_Description__c': 'Assigned to Pharmacology and Therapeutics Advisory Committee (PTAC) meeting to provide advice on Friday 18 August 2023', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Jul 2023', 'Status_History__c': 'a13OZ00000186u8YAA'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee <strong>recommended</strong> funding of sub-cutaneous tocilizumab for the treatment of giant cell arteritis (GCA) with a <strong>medium</strong> <strong>priority</strong>, within the context of rheumatology treatments, subject to Special Authority criteria, to be advised on by the Rheumatology Advisory Committee.</p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In making this recommendation, the Advisory Committee considered:</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The high unmet health need associated with GCA due to the chronic nature of GCA, prolonged treatment with steroids, and serious morbidity associated with both GCA, and chronic corticosteroid use.</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The evidence of benefit of tocilizumab in sustaining remission and reducing oral corticosteroid dose in those with GCA, whilst noting that the optimal treatment duration is unclear and relapse rate, following abrupt discontinuation of tocilizumab, is high (approximately 50%).</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The suitability advantages of a subcutaneous treatment in reducing pressures on hospital infusion services by allowing people with GCA and/or their caregivers to administer treatment at home.</p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee recommended Pharmac seek advice from the Rheumatology Specialist Advisory Committee regarding optimal treatment duration for tocilizumab for GCA, and Special Authority Criteria.\xa0</p>', 'fs': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee <strong>recommended</strong> funding of sub-cutaneous tocilizumab for the treatment of giant cell arteritis (GCA) with a <strong>medium</strong> <strong>priority</strong>, within the context of rheumatology treatments, subject to Special Authority criteria, to be advised on by the Rheumatology Advisory Committee.</p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In making this recommendation, the Advisory Committee considered:</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The high unmet health need associated with GCA due to the chronic nature of GCA, prolonged treatment with steroids, and serious morbidity associated with both GCA, and chronic corticosteroid use.</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The evidence of benefit of tocilizumab in sustaining remission and reducing oral corticosteroid dose in those with GCA, whilst noting that the optimal treatment duration is unclear and relapse rate, following abrupt discontinuation of tocilizumab, is high (approximately 50%).</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The suitability advantages of a subcutaneous treatment in reducing pressures on hospital infusion services by allowing people with GCA and/or their caregivers to administer treatment at home.</p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee recommended Pharmac seek advice from the Rheumatology Specialist Advisory Committee regarding optimal treatment duration for tocilizumab for GCA, and Special Authority Criteria.\xa0</p>', 'change': None}, 'Published_Discussion': {'s': '<h2><em>Māori impact</em></h2><p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee discussed the impact of funding tocilizumab for the treatment of GCA on Māori health areas of focus and Māori health outcomes. The Committee noted that Māori experienced a similar incidence of GCA to New Zealand Europeans (<a href=""https://pubmed.ncbi.nlm.nih.gov/35663155/"" target=""_blank"">Nagarajah et al. Rheumatol Adv Pract. 2022;6:rkac040</a>), however the Committee considered that outcome data comparing Māori to other populations was lacking. The Committee noted that nearly all cases of GCA are treated with high doses of prednisone for at least a year, and around 25% are still receiving treatment after five years (<a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9723338/"" target=""_blank"">Lyne et al. Front Med (Lausanne). 2022;9:1057917</a>). The Committee agreed with the Rheumatology Advisory Committee, who, in <a href=""https://pharmac.govt.nz/assets/2023-03-28-Rheumatology-Advisory-Committee-meeting-record.pdf"" target=""_blank"">March 2023,</a> considered that most of the comorbidities associated with corticosteroid use inequitably affect Māori, and thus considered that this should be taken into account when assessing alternative therapies such as tocilizumab. The Committee noted that GCA is not included within Hauora Arotahi (Māori health area of focus) in Te Whaioranga, Pharmac’s Māori Responsiveness Strategy.</p><h2><em>Impact on Pacific peoples, disabled people, tāngata whaikaha Māori, and people who have been underserved by the health system</em></h2><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the possible impact of funding tocilizumab for the treatment of GCA on Pacific peoples, disabled people, tāngata whaikaha Māori, and people who have been underserved by the health system. The Committee was not aware of any groups experiencing health inequities disproportionately affected by GCA.</p><h2><em>Background</em></h2><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that intravenous tocilizumab is currently <a href=""https://schedule.pharmac.govt.nz/2023/07/01/SA2159.pdf"" target=""_blank"">funded</a> in New Zealand for the treatment of cytokine release syndrome, rheumatoid arthritis, juvenile idiopathic arthritis (systemic and polyarticular), adult-onset Still’s disease, idiopathic multicentric Castleman’s disease, and moderate to severe COVID-19.</p><p><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the Rheumatology Advisory Committee reviewed an application for the funding of tocilizumab for the treatment of polymyalgia rheumatica (PMR) in <a href=""https://pharmac.govt.nz/assets/2023-03-28-Rheumatology-Advisory-Committee-meeting-record.pdf"" target=""_blank"">March 2023</a>, and recommended the application be deferred pending the availability of further evidence to define the intended population to treat, treatment duration, and the appropriate timing of when to start treatment. When making this recommendation, the Rheumatology Advisory Committee considered there was a high need to fund agents such as tocilizumab for GCA.</p><p><em>Health need</em></p><p><span style=""color: black;"">1.5.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that GCA (previously known as Horton’s disease or temporal arteritis) is a rare type of autoimmune chronic systemic vasculitis (inflammation of the blood vessels) that typically affects the cranial arteries (especially the temporal and ophthalmic arteries), and less commonly the branches of the aorta (<a href=""https://pubmed.ncbi.nlm.nih.gov/22285588/"" target=""_blank"">Borchers et al. Automimmun Rev. 2012;11:544-54</a>). The Committee noted that GCA is characterised by granulomatous inflammation of the three-layered vessel wall that results in vaso-occlusion, wall dissection, and aneurysm formation (<a href=""https://pubmed.ncbi.nlm.nih.gov/36656970/"" target=""_blank"">Weyand et al. Circ Res. 2023;132:238-50)</a>. The Committee noted that <span style=""color: black;"">although the exact cause of\xa0GCA is unknown, the </span>pathophysiology involves a multi-step process with a pronounced acute phase response involving pro-inflammatory cytokines, in particular IL-6 which is an important mediator of inflammation <a href=""https://pubmed.ncbi.nlm.nih.gov/22285588/"" target=""_blank"">(Borchers et al. Autoimmun Rev. 2012;11:544-54</a>, <a href=""https://pubmed.ncbi.nlm.nih.gov/26239828/"" target=""_blank"">Steel et al. Drugs Aging. 2015;32:591-9</a>).</p><p><span style=""color: black;"">1.6.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that PMR is closely linked to GCA, occurring in approximately 40-60% of people with GCA, although the precise nature of the relationship between GCA and PMR is not completely understood (<a href=""https://bpac.org.nz/bpj/2013/june/docs/BPJ53pages16-23.pdf"" target=""_blank"">bpac<sup>nz</sup>. 2013;53:17-23</a>). The Committee note that conversely, GCA is found in approximately 15-20% of people with PMR (<a href=""https://pubmed.ncbi.nlm.nih.gov/33706808/"" target=""_blank"">Li et al. Arthritis Res Ther. 2021;23:82</a>).</p><p><span style=""color: black;"">1.7.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the incidence of GCA increases with age, most commonly affecting people aged over 50 years, and is two to three times more common in females than males (<a href=""https://pubmed.ncbi.nlm.nih.gov/22285588/"" target=""_blank"">Borchers et al. Autoimmun Rev. 2012;11:544-54</a>, <a href=""https://pubmed.ncbi.nlm.nih.gov/26239828/"" target=""_blank"">Steel et al. Drugs Aging. 2015;32:591-9</a>).The Committee noted that from the literature, the highest reported rates of GCA are in northern Europe (especially in people of Scandinavian descent), although it can also affect other groups (<a href=""https://pubmed.ncbi.nlm.nih.gov/19790127/"" target=""_blank"">Gonzalez-Gay et al. Arthritis Rheum. 2009;6:1454)</a>. The Committee noted that the estimated incidence of GCA in New Zealand is 12.73 per 100,000 New Zealanders (<a href=""https://pubmed.ncbi.nlm.nih.gov/21475359/"" target=""_blank"">Abdul-Rahman et al. N Z Med J. 2011;124:44-52</a>), around 270 people are expected to be diagnosed with GCA each year in New Zealand.</p><p><span style=""color: black;"">1.8.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that Māori experience similar incidence of GCA to New Zealand Europeans (<a href=""https://pubmed.ncbi.nlm.nih.gov/35663155/"" target=""_blank"">Nagarajah et al. Rheumatol Adv Pract. 2022;6:rkac040</a>), however considered that outcome data comparing Māori to other populations is lacking. The Committee noted that nearly all cases of GCA are treated with high doses of prednisone for at least a year, and around 25% are still receiving treatment after five years (<a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9723338/"" target=""_blank"">Lyne et al. Front Med (Lausanne). 2022;9:1057917</a>). The Committee considered that steroid use differs between ophthalmology and rheumatology with visual problems caused by GCA requiring higher dose steroids The Committee agreed with the comments from the Rheumatology Advisory Committee in <a href=""https://pharmac.govt.nz/assets/2023-03-28-Rheumatology-Advisory-Committee-meeting-record.pdf"" target=""_blank"">March 2023</a>, that most of the comorbidities associated corticosteroid use inequitably affect Māori, and thus considered that this should be accounted for when assessing alternative therapies such as tocilizumab.</p><p><span style=""color: black;"">1.9.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the onset of symptoms in GCA tend to be subacute, but abrupt presentations over a few days can occur. The Committee noted that temporal headache is the most frequent symptom of GCA and will be present in approximately 75% of cases. The Committee noted that systemic features, including low-grade fever, anorexia, and fatigue are present in approximately half of those affected (<a href=""https://bpac.org.nz/bpj/2013/june/docs/BPJ53pages16-23.pdf"" target=""_blank"">bpac<sup>nz</sup>. 2013;53:17-23</a>). The Committee noted that if undetected, GCA can have catastrophic sequelae, such as irreversible visual loss, stroke, and aortic aneurysm development. The Committee noted that loss of vision can be permanent, and large-vessel stenosis, and with it an increased risk of stroke, occurs in 10-15% of people (<a href=""https://pubmed.ncbi.nlm.nih.gov/23253927/"" target=""_blank"">Kermani et al.. Ann Rheum Dis. 2013;72:1989-94</a>).</p><p><span style=""color: black;"">1.10.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that current treatment of GCA aims to dampen the acute inflammatory process, thereby preventing ischemic complications, prevent disease relapses using the lowest effective dose (if any) of corticosteroids, and prevent long-term vascular damage (ie aneurysm, vascular rupture, and stenosis) (<a href=""https://pubmed.ncbi.nlm.nih.gov/36344353/"" target=""_blank"">Farina et al. Eur J Intern Med. 2023;107:17-26</a>).</p><p><span style=""color: black;"">1.11.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that the European Alliance of Associations for Rheumatology (EULAR) and British Society for Rheumatology (BSR) guidelines recommend starting treatment with high-dose corticosteroid therapy for a minimum of four weeks, gradually tapering the course, and adding methotrexate if flares occur.</p><p><span style=""color: black;"">1.12.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that GCA can impact on the whānau of individuals with GCA due to the effect of the disease on friendships and relationships, the affected individual’s ability to work, support children, and take part in recreational activities whilst symptomatic. The Committee considered that the chronic nature of GCA, prolonged treatment with steroids, and serious morbidity described all contribute to the currently high unmet health need of the condition.</p><p><em>Health benefit</em></p><p><span style=""color: black;"">1.13.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted tocilizumab is a humanised monoclonal antibody that targets the interleukin-6 (IL-6) receptor which is involved in immunological and inflammatory reactions. The Committee noted that only the subcutaneous formulation of tocilizumab is <a href=""https://medsafe.govt.nz/profs/Datasheet/a/Actemrainf.pdf"" target=""_blank"">approved by Medsafe</a> for the treatment of GCA in adults. The Committee noted that the recommended dose of tocilizumab for adults with GCA is 162 mg once weekly as a subcutaneous injection, in combination with a tapering course of corticosteroids. The Committee noted that tocilizumab may be used alone following discontinuation of corticosteroids. The Committee noted that tocilizumab is currently recommended for the treatment of GCA in <a href=""https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2019-03/files/tocilizumab-GCA-psd-march-2019.pdf"" target=""_blank"">Australia,</a> <a href=""https://www.cadth.ca/sites/default/files/cdr/complete/SR0534_Actemra_GCA_complete_Mar-27-18.pdf"" target=""_blank"">Canada</a>, <a href=""https://www.scottishmedicines.org.uk/media/3693/tocilizumab-roactemra-final-august-2018-for-website.pdf"" target=""_blank"">Scotland</a>, and <a href=""https://www.nice.org.uk/guidance/TA518/chapter/1-Recommendations"" target=""_blank"">England/Wales</a>. The Committee noted that tocilizumab does not treat GCA but rather dampens the inflammatory process.</p><p><span style=""color: black;"">1.14.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that the applicant suggests that the current treatment algorithm (corticosteroid monotherapy) is altered to include tocilizumab for both new-onset (first line), and flare management (second line) treatment of GCA. The Committee considered agreed with the applicants view of the treatment algorithm. The Committee considered that patients not responding to current treatment would receive higher doses, and many patients would also receive methotrexate.</p><p><span style=""color: black;"">1.15.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Giant-Cell Arteritis Actemra (GiACTA) trial provided the primary evidence for tocilizumab for the treatment of GCA (<a href=""https://pubmed.ncbi.nlm.nih.gov/28745999/"" target=""_blank"">Stone et al. 2017. N Engl J Med. 2017;377:317-28</a>, <a href=""https://pubmed.ncbi.nlm.nih.gov/34718434/"" target=""_blank"">Stone et al. Rheumatology (Oxford). 2022;61:2915-22</a>, <a href=""https://pubmed.ncbi.nlm.nih.gov/30915462/"" target=""_blank"">Adler et al. Rheumatology (Oxford).2019;58:1639-43</a>, <a href=""https://pubmed.ncbi.nlm.nih.gov/30786937/"" target=""_blank"">Strand et al. Arthritis Res Ther. 2019;21:64</a>). The Committee noted that the trial was a phase III, randomised, double-blind, placebo-controlled, multicentre study of adult patients with either new onset or relapsing GCA (<em>N</em>=251) who were randomised in a 1:1:2:1 ratio to receive the following treatments for 52 weeks:</p><p class=""ql-indent-1""><span style=""font-size: 11pt; font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 11pt;"">Placebo subcutaneously (SC) weekly (QW) + 26-week prednisone taper regimen (PBO + 26 week; </span><em style=""font-size: 11pt;"">n=</em><span style=""font-size: 11pt;"">50) </span></p><p class=""ql-indent-1""><span style=""font-size: 11pt; font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 11pt;"">Placebo SC QW + 52-week prednisone taper regimen (PBO + 52 week; </span><em style=""font-size: 11pt;"">n=</em><span style=""font-size: 11pt;"">50) </span></p><p class=""ql-indent-1""><span style=""font-size: 11pt; font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 11pt;"">162 mg tocilizumab SC QW + 26-week prednisone taper regimen (tocilizumab QW; </span><em style=""font-size: 11pt;"">n</em><span style=""font-size: 11pt;"">=100) </span></p><p class=""ql-indent-1""><span style=""font-size: 11pt; font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 11pt;"">162 mg tocilizumab SC every other week (Q2W) + 26-week prednisone taper regimen (tocilizumab Q2W; </span><em style=""font-size: 11pt;"">n</em><span style=""font-size: 11pt;"">=50)</span></p><p class=""ql-indent-2"">1.15.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that after the 52-week double-blind treatment period (Part 1), all patients who had completed Part 1 of the study were eligible to enter the 104-week open-label extension of the study.</p><p class=""ql-indent-2"">1.15.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that the primary endpoint was proportion of patients in sustained remission from weeks 12 to 52 with adherence to a standardised 26-week (short course) corticosteroid taper compared with a 26-week corticosteroid taper given alone in the placebo group. The Committee noted that sustained remission at week 52 was 56% tocilizumab weekly (QW) and in 53% tocilizumab every two weeks (Q2W), 14% placebo group with 26-week prednisone taper and 18% in the placebo group with 52-week prednisone taper (<em>P</em>&lt;0.001 for the comparisons of either active treatment with placebo).</p><p class=""ql-indent-2"">1.15.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted the following results from secondary endpoints:</p><p class=""ql-indent-3""><span style=""font-size: 11pt; font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 11pt;"">Less prednisone used in the tocilizumab groups than placebo over 52 weeks.</span></p><p class=""ql-indent-3""><span style=""font-size: 11pt; font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 11pt;"">Fewer flares in the tocilizumab groups than placebo over 52 weeks, and over the 3-year extension period.</span></p><p class=""ql-indent-3""><span style=""font-size: 11pt; font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 11pt;"">In patients with new-onset and relapsing disease, the median time to first flare in the tocilizumab QW group was 577 and 575\u2009days, respectively, vs 479 and 428\u2009days with tocilizumab Q2W and 179 and 224\u2009days with placebo.</span></p><p class=""ql-indent-2"">1.15.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that there was a mean increase of the 36-item short form survey (SF-36) quality of life measure in the groups that received tocilizumab, and a decreased SF-36 in groups that received placebo. The Committee noted that the improved quality of life was greater in the group that receive tocilizumab weekly than in the group that received tocilizumab every two weeks.</p><p><span style=""color: black;"">1.16.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that tocilizumab was a reasonably safe treatment for GCA, noting that no deaths occurred in the first 52 weeks of the GiACTA trial, and that withdrawal from the trial due to adverse events occurred in 6% of the patients in each tocilizumab group, 4% placebo with 26-week taper, and none in the other placebo group.</p><p><span style=""color: black;"">1.17.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted the results of a two-year open-label extension phase of the GiACTA trial and a previous phase II trial. The Committee considered these trials demonstrated that the relapse rate following abrupt discontinuation of tocilizumab is high, noting that more than 50% of those achieving remission on tocilizumab later relapsed once treatment was stopped (<a href=""https://pubmed.ncbi.nlm.nih.gov/30915462/"" target=""_blank"">Adler et al. Rheumatology (Oxford).2019;58:1639-43</a>, <a href=""https://www.sciencedirect.com/science/article/abs/pii/S2665991321000382"" target=""_blank"">Stone et al. Lancet Rheumatol. 2021;3:e328-36</a>). The Committee considered that there is currently insufficient evidence to define optimal duration of treatment and dosing schedule beyond 12 months for tocilizumab for GCA, but the above evidence suggested that treatment may need to be continued for longer than 12 months. The Committee considered that for people in remission after 12 months of treatment, a dose reduction of tocilizumab may be appropriate. However, the Committee noted that those from the extension study who received weekly (QW) tocilizumab experienced less flares, and improved quality of life in comparison to those who received tocilizumab every 2 weeks.\xa0(<a href=""https://pubmed.ncbi.nlm.nih.gov/36377586/"" target=""_blank"">Calderon-Goerke et al, Clin Exp Rheumatol. 2023;41:829-36,</a> <a href=""https://ard.bmj.com/content/80/Suppl_1/655.1"" target=""_blank"">Rakholiya et al. An Rheum Dis. 2021;80:655</a>, <a href=""https://pubmed.ncbi.nlm.nih.gov/36774660/"" target=""_blank"">Tomelleri et al. Semin Arthritis Rheum. 2023;59:152-74).</a></p><p><span style=""color: black;"">1.18.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that there are differing recommendations on when to start tocilizumab for GCA; the <a href=""https://pubmed.ncbi.nlm.nih.gov/34235884/"" target=""_blank"">American College of Rheumatology/Vasculitis Foundation (ACR/VF)</a> recommended tocilizumab for all patients with newly diagnosed GCA, and the <a href=""https://ard.bmj.com/content/79/1/19"" target=""_blank"">European Alliance of Associations for Rheumatology (EULAR</a>) recommended tocilizumab in those with, or at risk of, corticosteroid-related adverse events or in patients who have relapsing disease. The Committee considered that New Zealand practice would likely align with the EULAR recommendations.</p><p><span style=""color: black;"">1.19.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that the evidence for tocilizumab in GCA was of good quality due to the GiACTA trial’s methodology and duration of the study.\xa0</p><p><span style=""color: black;"">1.20.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that there is currently no data available on the use of intravenous tocilizumab for the treatment of GCA, although considered that it is expected that intravenous and subcutaneous tocilizumab are likely to provide the same or similar efficacy for this condition.</p><p><em>Suitability</em></p><p><span style=""color: black;"">1.21.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that tocilizumab subcutaneous injections are available as pre-filled syringes and are self-administered. The Committee considered that individuals would require training for self-administration. The Committee noted that as per the <a href=""https://medsafe.govt.nz/profs/Datasheet/a/Actemrainf.pdf"" target=""_blank"">Medsafe datasheet</a>, the syringes require refrigeration, and once removed from the refrigerator can be stored up to 14 days at or below 30°C.</p><p><span style=""color: black;"">1.22.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered the advantages of the availability of a subcutaneous tocilizumab formulation for the treatment of GC. The Committee considered that a subcutaneous treatment would ease pressure on hospital and community infusion services, and allow people to self-administer, or have a caregiver help to administer at home which would improve access for people located rurally and/or unable to travel to infusion centre. Members noted that there would likely still be a health system and personal cost for those people who require or prefer health-professional administration of subcutaneous treatment.</p><p><em>Cost and savings</em></p><p><span style=""color: black;"">1.23.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that treatment of GCA with tocilizumab may reduce the cost of treating disease flares, including the number of healthcare practitioner visits. The Committee considered that treatment with high-dose long-term corticosteroids increases the risk of fractures, obesity, diabetes, cardiovascular disease, and serious infections; therefore, treatment that reduces the risk of these adverse effects is likely to result in health benefits and savings to the health sector.</p><p><span style=""color: black;"">1.24.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that patient number and uptake estimates appeared reasonable.<em> </em></p><p><span style=""color: black;"">1.25.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>\xa0The Committee considered it is difficult to estimate the cost of tocilizumab treatment due to the uncertainty regarding treatment duration. The Committee considered it likely that at least 50% of people would receive treatment beyond 12 months. The Committee considered there may be a cost for radiology services to assess blood vessel inflammatory response to treatment, and that there may be increased referrals to rheumatology services to access diagnosis and subsequent treatment.</p><p><em>Funding criteria</em></p><p><span style=""color: black;"">1.26.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that future funding criteria would require a definitive diagnosis of GCA. The Committee considered that people may need to have completed a trial of methotrexate (3-6 months) before accessing tocilizumab. The Committee also considered that there should be a restriction surrounding corticosteroid dose tapering, suggesting that less than 10 mg was ineffective, despite a maximum appropriate dose of methotrexate.</p><p><em>Summary for assessment</em></p><p><span style=""color: black;"">1.27.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""color: black;"">The Advisory Committee considered that the table below summarises its interpretation of the most appropriate PICO (population, intervention, comparator, outcomes) information for tocilizumab if it were to be funded in New Zealand for [the indication]. This PICO captures key clinical aspects of the proposal and may be used to frame any future economic assessment by Pharmac staff. This PICO is based on the Advisory Committee’s assessment at this time and may differ from that requested by the applicant. The PICO may change based on new information, additional clinical advice, or further analysis by Pharmac staff.</span></p><p><span style=""color: black;"">1.28.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""color: black;"">The Advisory Committee noted that elements of in the</span><em style=""color: black;""> </em><span style=""color: black;"">PICO (population, intervention, comparator, outcomes) for this application is unclear/uncertain at this time. The PICO may develop based on new information, additional clinical advice, or further analysis by Pharmac staff.</span></p><p><span style=""color: black;"">\ufeff</span><img src=""/apptracker/servlet/rtaImage?eid=a0POZ000004CpcO&amp;feoid=00N2P000000YsIc&amp;refid=0EMOZ000000Tqxh"" alt=""image.png""></img></p>', 'fs': '<h2><em>Māori impact</em></h2><p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee discussed the impact of funding tocilizumab for the treatment of GCA on Māori health areas of focus and Māori health outcomes. The Committee noted that Māori experienced a similar incidence of GCA to New Zealand Europeans (<a href=""https://pubmed.ncbi.nlm.nih.gov/35663155/"" target=""_blank"">Nagarajah et al. Rheumatol Adv Pract. 2022;6:rkac040</a>), however the Committee considered that outcome data comparing Māori to other populations was lacking. The Committee noted that nearly all cases of GCA are treated with high doses of prednisone for at least a year, and around 25% are still receiving treatment after five years (<a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9723338/"" target=""_blank"">Lyne et al. Front Med (Lausanne). 2022;9:1057917</a>). The Committee agreed with the Rheumatology Advisory Committee, who, in <a href=""https://pharmac.govt.nz/assets/2023-03-28-Rheumatology-Advisory-Committee-meeting-record.pdf"" target=""_blank"">March 2023,</a> considered that most of the comorbidities associated with corticosteroid use inequitably affect Māori, and thus considered that this should be taken into account when assessing alternative therapies such as tocilizumab. The Committee noted that GCA is not included within Hauora Arotahi (Māori health area of focus) in Te Whaioranga, Pharmac’s Māori Responsiveness Strategy.</p><h2><em>Impact on Pacific peoples, disabled people, tāngata whaikaha Māori, and people who have been underserved by the health system</em></h2><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the possible impact of funding tocilizumab for the treatment of GCA on Pacific peoples, disabled people, tāngata whaikaha Māori, and people who have been underserved by the health system. The Committee was not aware of any groups experiencing health inequities disproportionately affected by GCA.</p><h2><em>Background</em></h2><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that intravenous tocilizumab is currently <a href=""https://schedule.pharmac.govt.nz/2023/07/01/SA2159.pdf"" target=""_blank"">funded</a> in New Zealand for the treatment of cytokine release syndrome, rheumatoid arthritis, juvenile idiopathic arthritis (systemic and polyarticular), adult-onset Still’s disease, idiopathic multicentric Castleman’s disease, and moderate to severe COVID-19.</p><p><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the Rheumatology Advisory Committee reviewed an application for the funding of tocilizumab for the treatment of polymyalgia rheumatica (PMR) in <a href=""https://pharmac.govt.nz/assets/2023-03-28-Rheumatology-Advisory-Committee-meeting-record.pdf"" target=""_blank"">March 2023</a>, and recommended the application be deferred pending the availability of further evidence to define the intended population to treat, treatment duration, and the appropriate timing of when to start treatment. When making this recommendation, the Rheumatology Advisory Committee considered there was a high need to fund agents such as tocilizumab for GCA.</p><p><em>Health need</em></p><p><span style=""color: black;"">1.5.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that GCA (previously known as Horton’s disease or temporal arteritis) is a rare type of autoimmune chronic systemic vasculitis (inflammation of the blood vessels) that typically affects the cranial arteries (especially the temporal and ophthalmic arteries), and less commonly the branches of the aorta (<a href=""https://pubmed.ncbi.nlm.nih.gov/22285588/"" target=""_blank"">Borchers et al. Automimmun Rev. 2012;11:544-54</a>). The Committee noted that GCA is characterised by granulomatous inflammation of the three-layered vessel wall that results in vaso-occlusion, wall dissection, and aneurysm formation (<a href=""https://pubmed.ncbi.nlm.nih.gov/36656970/"" target=""_blank"">Weyand et al. Circ Res. 2023;132:238-50)</a>. The Committee noted that <span style=""color: black;"">although the exact cause of\xa0GCA is unknown, the </span>pathophysiology involves a multi-step process with a pronounced acute phase response involving pro-inflammatory cytokines, in particular IL-6 which is an important mediator of inflammation <a href=""https://pubmed.ncbi.nlm.nih.gov/22285588/"" target=""_blank"">(Borchers et al. Autoimmun Rev. 2012;11:544-54</a>, <a href=""https://pubmed.ncbi.nlm.nih.gov/26239828/"" target=""_blank"">Steel et al. Drugs Aging. 2015;32:591-9</a>).</p><p><span style=""color: black;"">1.6.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that PMR is closely linked to GCA, occurring in approximately 40-60% of people with GCA, although the precise nature of the relationship between GCA and PMR is not completely understood (<a href=""https://bpac.org.nz/bpj/2013/june/docs/BPJ53pages16-23.pdf"" target=""_blank"">bpac<sup>nz</sup>. 2013;53:17-23</a>). The Committee note that conversely, GCA is found in approximately 15-20% of people with PMR (<a href=""https://pubmed.ncbi.nlm.nih.gov/33706808/"" target=""_blank"">Li et al. Arthritis Res Ther. 2021;23:82</a>).</p><p><span style=""color: black;"">1.7.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the incidence of GCA increases with age, most commonly affecting people aged over 50 years, and is two to three times more common in females than males (<a href=""https://pubmed.ncbi.nlm.nih.gov/22285588/"" target=""_blank"">Borchers et al. Autoimmun Rev. 2012;11:544-54</a>, <a href=""https://pubmed.ncbi.nlm.nih.gov/26239828/"" target=""_blank"">Steel et al. Drugs Aging. 2015;32:591-9</a>).The Committee noted that from the literature, the highest reported rates of GCA are in northern Europe (especially in people of Scandinavian descent), although it can also affect other groups (<a href=""https://pubmed.ncbi.nlm.nih.gov/19790127/"" target=""_blank"">Gonzalez-Gay et al. Arthritis Rheum. 2009;6:1454)</a>. The Committee noted that the estimated incidence of GCA in New Zealand is 12.73 per 100,000 New Zealanders (<a href=""https://pubmed.ncbi.nlm.nih.gov/21475359/"" target=""_blank"">Abdul-Rahman et al. N Z Med J. 2011;124:44-52</a>), around 270 people are expected to be diagnosed with GCA each year in New Zealand.</p><p><span style=""color: black;"">1.8.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that Māori experience similar incidence of GCA to New Zealand Europeans (<a href=""https://pubmed.ncbi.nlm.nih.gov/35663155/"" target=""_blank"">Nagarajah et al. Rheumatol Adv Pract. 2022;6:rkac040</a>), however considered that outcome data comparing Māori to other populations is lacking. The Committee noted that nearly all cases of GCA are treated with high doses of prednisone for at least a year, and around 25% are still receiving treatment after five years (<a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9723338/"" target=""_blank"">Lyne et al. Front Med (Lausanne). 2022;9:1057917</a>). The Committee considered that steroid use differs between ophthalmology and rheumatology with visual problems caused by GCA requiring higher dose steroids The Committee agreed with the comments from the Rheumatology Advisory Committee in <a href=""https://pharmac.govt.nz/assets/2023-03-28-Rheumatology-Advisory-Committee-meeting-record.pdf"" target=""_blank"">March 2023</a>, that most of the comorbidities associated corticosteroid use inequitably affect Māori, and thus considered that this should be accounted for when assessing alternative therapies such as tocilizumab.</p><p><span style=""color: black;"">1.9.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the onset of symptoms in GCA tend to be subacute, but abrupt presentations over a few days can occur. The Committee noted that temporal headache is the most frequent symptom of GCA and will be present in approximately 75% of cases. The Committee noted that systemic features, including low-grade fever, anorexia, and fatigue are present in approximately half of those affected (<a href=""https://bpac.org.nz/bpj/2013/june/docs/BPJ53pages16-23.pdf"" target=""_blank"">bpac<sup>nz</sup>. 2013;53:17-23</a>). The Committee noted that if undetected, GCA can have catastrophic sequelae, such as irreversible visual loss, stroke, and aortic aneurysm development. The Committee noted that loss of vision can be permanent, and large-vessel stenosis, and with it an increased risk of stroke, occurs in 10-15% of people (<a href=""https://pubmed.ncbi.nlm.nih.gov/23253927/"" target=""_blank"">Kermani et al.. Ann Rheum Dis. 2013;72:1989-94</a>).</p><p><span style=""color: black;"">1.10.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that current treatment of GCA aims to dampen the acute inflammatory process, thereby preventing ischemic complications, prevent disease relapses using the lowest effective dose (if any) of corticosteroids, and prevent long-term vascular damage (ie aneurysm, vascular rupture, and stenosis) (<a href=""https://pubmed.ncbi.nlm.nih.gov/36344353/"" target=""_blank"">Farina et al. Eur J Intern Med. 2023;107:17-26</a>).</p><p><span style=""color: black;"">1.11.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that the European Alliance of Associations for Rheumatology (EULAR) and British Society for Rheumatology (BSR) guidelines recommend starting treatment with high-dose corticosteroid therapy for a minimum of four weeks, gradually tapering the course, and adding methotrexate if flares occur.</p><p><span style=""color: black;"">1.12.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that GCA can impact on the whānau of individuals with GCA due to the effect of the disease on friendships and relationships, the affected individual’s ability to work, support children, and take part in recreational activities whilst symptomatic. The Committee considered that the chronic nature of GCA, prolonged treatment with steroids, and serious morbidity described all contribute to the currently high unmet health need of the condition.</p><p><em>Health benefit</em></p><p><span style=""color: black;"">1.13.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted tocilizumab is a humanised monoclonal antibody that targets the interleukin-6 (IL-6) receptor which is involved in immunological and inflammatory reactions. The Committee noted that only the subcutaneous formulation of tocilizumab is <a href=""https://medsafe.govt.nz/profs/Datasheet/a/Actemrainf.pdf"" target=""_blank"">approved by Medsafe</a> for the treatment of GCA in adults. The Committee noted that the recommended dose of tocilizumab for adults with GCA is 162 mg once weekly as a subcutaneous injection, in combination with a tapering course of corticosteroids. The Committee noted that tocilizumab may be used alone following discontinuation of corticosteroids. The Committee noted that tocilizumab is currently recommended for the treatment of GCA in <a href=""https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2019-03/files/tocilizumab-GCA-psd-march-2019.pdf"" target=""_blank"">Australia,</a> <a href=""https://www.cadth.ca/sites/default/files/cdr/complete/SR0534_Actemra_GCA_complete_Mar-27-18.pdf"" target=""_blank"">Canada</a>, <a href=""https://www.scottishmedicines.org.uk/media/3693/tocilizumab-roactemra-final-august-2018-for-website.pdf"" target=""_blank"">Scotland</a>, and <a href=""https://www.nice.org.uk/guidance/TA518/chapter/1-Recommendations"" target=""_blank"">England/Wales</a>. The Committee noted that tocilizumab does not treat GCA but rather dampens the inflammatory process.</p><p><span style=""color: black;"">1.14.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that the applicant suggests that the current treatment algorithm (corticosteroid monotherapy) is altered to include tocilizumab for both new-onset (first line), and flare management (second line) treatment of GCA. The Committee considered agreed with the applicants view of the treatment algorithm. The Committee considered that patients not responding to current treatment would receive higher doses, and many patients would also receive methotrexate.</p><p><span style=""color: black;"">1.15.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Giant-Cell Arteritis Actemra (GiACTA) trial provided the primary evidence for tocilizumab for the treatment of GCA (<a href=""https://pubmed.ncbi.nlm.nih.gov/28745999/"" target=""_blank"">Stone et al. 2017. N Engl J Med. 2017;377:317-28</a>, <a href=""https://pubmed.ncbi.nlm.nih.gov/34718434/"" target=""_blank"">Stone et al. Rheumatology (Oxford). 2022;61:2915-22</a>, <a href=""https://pubmed.ncbi.nlm.nih.gov/30915462/"" target=""_blank"">Adler et al. Rheumatology (Oxford).2019;58:1639-43</a>, <a href=""https://pubmed.ncbi.nlm.nih.gov/30786937/"" target=""_blank"">Strand et al. Arthritis Res Ther. 2019;21:64</a>). The Committee noted that the trial was a phase III, randomised, double-blind, placebo-controlled, multicentre study of adult patients with either new onset or relapsing GCA (<em>N</em>=251) who were randomised in a 1:1:2:1 ratio to receive the following treatments for 52 weeks:</p><p class=""ql-indent-1""><span style=""font-size: 11pt; font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 11pt;"">Placebo subcutaneously (SC) weekly (QW) + 26-week prednisone taper regimen (PBO + 26 week; </span><em style=""font-size: 11pt;"">n=</em><span style=""font-size: 11pt;"">50) </span></p><p class=""ql-indent-1""><span style=""font-size: 11pt; font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 11pt;"">Placebo SC QW + 52-week prednisone taper regimen (PBO + 52 week; </span><em style=""font-size: 11pt;"">n=</em><span style=""font-size: 11pt;"">50) </span></p><p class=""ql-indent-1""><span style=""font-size: 11pt; font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 11pt;"">162 mg tocilizumab SC QW + 26-week prednisone taper regimen (tocilizumab QW; </span><em style=""font-size: 11pt;"">n</em><span style=""font-size: 11pt;"">=100) </span></p><p class=""ql-indent-1""><span style=""font-size: 11pt; font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 11pt;"">162 mg tocilizumab SC every other week (Q2W) + 26-week prednisone taper regimen (tocilizumab Q2W; </span><em style=""font-size: 11pt;"">n</em><span style=""font-size: 11pt;"">=50)</span></p><p class=""ql-indent-2"">1.15.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that after the 52-week double-blind treatment period (Part 1), all patients who had completed Part 1 of the study were eligible to enter the 104-week open-label extension of the study.</p><p class=""ql-indent-2"">1.15.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that the primary endpoint was proportion of patients in sustained remission from weeks 12 to 52 with adherence to a standardised 26-week (short course) corticosteroid taper compared with a 26-week corticosteroid taper given alone in the placebo group. The Committee noted that sustained remission at week 52 was 56% tocilizumab weekly (QW) and in 53% tocilizumab every two weeks (Q2W), 14% placebo group with 26-week prednisone taper and 18% in the placebo group with 52-week prednisone taper (<em>P</em>&lt;0.001 for the comparisons of either active treatment with placebo).</p><p class=""ql-indent-2"">1.15.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted the following results from secondary endpoints:</p><p class=""ql-indent-3""><span style=""font-size: 11pt; font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 11pt;"">Less prednisone used in the tocilizumab groups than placebo over 52 weeks.</span></p><p class=""ql-indent-3""><span style=""font-size: 11pt; font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 11pt;"">Fewer flares in the tocilizumab groups than placebo over 52 weeks, and over the 3-year extension period.</span></p><p class=""ql-indent-3""><span style=""font-size: 11pt; font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 11pt;"">In patients with new-onset and relapsing disease, the median time to first flare in the tocilizumab QW group was 577 and 575\u2009days, respectively, vs 479 and 428\u2009days with tocilizumab Q2W and 179 and 224\u2009days with placebo.</span></p><p class=""ql-indent-2"">1.15.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that there was a mean increase of the 36-item short form survey (SF-36) quality of life measure in the groups that received tocilizumab, and a decreased SF-36 in groups that received placebo. The Committee noted that the improved quality of life was greater in the group that receive tocilizumab weekly than in the group that received tocilizumab every two weeks.</p><p><span style=""color: black;"">1.16.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that tocilizumab was a reasonably safe treatment for GCA, noting that no deaths occurred in the first 52 weeks of the GiACTA trial, and that withdrawal from the trial due to adverse events occurred in 6% of the patients in each tocilizumab group, 4% placebo with 26-week taper, and none in the other placebo group.</p><p><span style=""color: black;"">1.17.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted the results of a two-year open-label extension phase of the GiACTA trial and a previous phase II trial. The Committee considered these trials demonstrated that the relapse rate following abrupt discontinuation of tocilizumab is high, noting that more than 50% of those achieving remission on tocilizumab later relapsed once treatment was stopped (<a href=""https://pubmed.ncbi.nlm.nih.gov/30915462/"" target=""_blank"">Adler et al. Rheumatology (Oxford).2019;58:1639-43</a>, <a href=""https://www.sciencedirect.com/science/article/abs/pii/S2665991321000382"" target=""_blank"">Stone et al. Lancet Rheumatol. 2021;3:e328-36</a>). The Committee considered that there is currently insufficient evidence to define optimal duration of treatment and dosing schedule beyond 12 months for tocilizumab for GCA, but the above evidence suggested that treatment may need to be continued for longer than 12 months. The Committee considered that for people in remission after 12 months of treatment, a dose reduction of tocilizumab may be appropriate. However, the Committee noted that those from the extension study who received weekly (QW) tocilizumab experienced less flares, and improved quality of life in comparison to those who received tocilizumab every 2 weeks.\xa0(<a href=""https://pubmed.ncbi.nlm.nih.gov/36377586/"" target=""_blank"">Calderon-Goerke et al, Clin Exp Rheumatol. 2023;41:829-36,</a> <a href=""https://ard.bmj.com/content/80/Suppl_1/655.1"" target=""_blank"">Rakholiya et al. An Rheum Dis. 2021;80:655</a>, <a href=""https://pubmed.ncbi.nlm.nih.gov/36774660/"" target=""_blank"">Tomelleri et al. Semin Arthritis Rheum. 2023;59:152-74).</a></p><p><span style=""color: black;"">1.18.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that there are differing recommendations on when to start tocilizumab for GCA; the <a href=""https://pubmed.ncbi.nlm.nih.gov/34235884/"" target=""_blank"">American College of Rheumatology/Vasculitis Foundation (ACR/VF)</a> recommended tocilizumab for all patients with newly diagnosed GCA, and the <a href=""https://ard.bmj.com/content/79/1/19"" target=""_blank"">European Alliance of Associations for Rheumatology (EULAR</a>) recommended tocilizumab in those with, or at risk of, corticosteroid-related adverse events or in patients who have relapsing disease. The Committee considered that New Zealand practice would likely align with the EULAR recommendations.</p><p><span style=""color: black;"">1.19.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that the evidence for tocilizumab in GCA was of good quality due to the GiACTA trial’s methodology and duration of the study.\xa0</p><p><span style=""color: black;"">1.20.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that there is currently no data available on the use of intravenous tocilizumab for the treatment of GCA, although considered that it is expected that intravenous and subcutaneous tocilizumab are likely to provide the same or similar efficacy for this condition.</p><p><em>Suitability</em></p><p><span style=""color: black;"">1.21.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that tocilizumab subcutaneous injections are available as pre-filled syringes and are self-administered. The Committee considered that individuals would require training for self-administration. The Committee noted that as per the <a href=""https://medsafe.govt.nz/profs/Datasheet/a/Actemrainf.pdf"" target=""_blank"">Medsafe datasheet</a>, the syringes require refrigeration, and once removed from the refrigerator can be stored up to 14 days at or below 30°C.</p><p><span style=""color: black;"">1.22.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered the advantages of the availability of a subcutaneous tocilizumab formulation for the treatment of GC. The Committee considered that a subcutaneous treatment would ease pressure on hospital and community infusion services, and allow people to self-administer, or have a caregiver help to administer at home which would improve access for people located rurally and/or unable to travel to infusion centre. Members noted that there would likely still be a health system and personal cost for those people who require or prefer health-professional administration of subcutaneous treatment.</p><p><em>Cost and savings</em></p><p><span style=""color: black;"">1.23.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that treatment of GCA with tocilizumab may reduce the cost of treating disease flares, including the number of healthcare practitioner visits. The Committee considered that treatment with high-dose long-term corticosteroids increases the risk of fractures, obesity, diabetes, cardiovascular disease, and serious infections; therefore, treatment that reduces the risk of these adverse effects is likely to result in health benefits and savings to the health sector.</p><p><span style=""color: black;"">1.24.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that patient number and uptake estimates appeared reasonable.<em> </em></p><p><span style=""color: black;"">1.25.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>\xa0The Committee considered it is difficult to estimate the cost of tocilizumab treatment due to the uncertainty regarding treatment duration. The Committee considered it likely that at least 50% of people would receive treatment beyond 12 months. The Committee considered there may be a cost for radiology services to assess blood vessel inflammatory response to treatment, and that there may be increased referrals to rheumatology services to access diagnosis and subsequent treatment.</p><p><em>Funding criteria</em></p><p><span style=""color: black;"">1.26.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that future funding criteria would require a definitive diagnosis of GCA. The Committee considered that people may need to have completed a trial of methotrexate (3-6 months) before accessing tocilizumab. The Committee also considered that there should be a restriction surrounding corticosteroid dose tapering, suggesting that less than 10 mg was ineffective, despite a maximum appropriate dose of methotrexate.</p><p><em>Summary for assessment</em></p><p><span style=""color: black;"">1.27.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""color: black;"">The Advisory Committee considered that the table below summarises its interpretation of the most appropriate PICO (population, intervention, comparator, outcomes) information for tocilizumab if it were to be funded in New Zealand for [the indication]. This PICO captures key clinical aspects of the proposal and may be used to frame any future economic assessment by Pharmac staff. This PICO is based on the Advisory Committee’s assessment at this time and may differ from that requested by the applicant. The PICO may change based on new information, additional clinical advice, or further analysis by Pharmac staff.</span></p><p><span style=""color: black;"">1.28.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""color: black;"">The Advisory Committee noted that elements of in the</span><em style=""color: black;""> </em><span style=""color: black;"">PICO (population, intervention, comparator, outcomes) for this application is unclear/uncertain at this time. The PICO may develop based on new information, additional clinical advice, or further analysis by Pharmac staff.</span></p><p><span style=""color: black;"">\ufeff</span><img src=""/apptracker/servlet/rtaImage?eid=a0POZ000004CpcO&amp;feoid=00N2P000000YsIc&amp;refid=0EMOZ000000Tqxh"" alt=""image.png""></img></p>', 'change': None}, 'Published_Application': {'s': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee reviewed the application for tocilizumab for the treatment of giant cell arteritis.</p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee took into account, where applicable, Pharmac’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'fs': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee reviewed the application for tocilizumab for the treatment of giant cell arteritis.</p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee took into account, where applicable, Pharmac’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Medium', 'fs': 'Medium', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Nov 2023', 'fs': 'Nov 2023', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Friday 18 August 2023.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Friday 18 August 2023.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000004CpcO2AS'}, 'Id': 'a0POZ000004CpcO2AS', 'Event_Date__c': '2023-11-03', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Friday 18 August 2023.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'Medium', 'Formatted_Date__c': 'Nov 2023', 'Published_Recommendation__c': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee <strong>recommended</strong> funding of sub-cutaneous tocilizumab for the treatment of giant cell arteritis (GCA) with a <strong>medium</strong> <strong>priority</strong>, within the context of rheumatology treatments, subject to Special Authority criteria, to be advised on by the Rheumatology Advisory Committee.</p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In making this recommendation, the Advisory Committee considered:</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The high unmet health need associated with GCA due to the chronic nature of GCA, prolonged treatment with steroids, and serious morbidity associated with both GCA, and chronic corticosteroid use.</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The evidence of benefit of tocilizumab in sustaining remission and reducing oral corticosteroid dose in those with GCA, whilst noting that the optimal treatment duration is unclear and relapse rate, following abrupt discontinuation of tocilizumab, is high (approximately 50%).</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The suitability advantages of a subcutaneous treatment in reducing pressures on hospital infusion services by allowing people with GCA and/or their caregivers to administer treatment at home.</p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee recommended Pharmac seek advice from the Rheumatology Specialist Advisory Committee regarding optimal treatment duration for tocilizumab for GCA, and Special Authority Criteria.\xa0</p>', 'Published_Application__c': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee reviewed the application for tocilizumab for the treatment of giant cell arteritis.</p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee took into account, where applicable, Pharmac’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'Published_Discussion__c': '<h2><em>Māori impact</em></h2><p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee discussed the impact of funding tocilizumab for the treatment of GCA on Māori health areas of focus and Māori health outcomes. The Committee noted that Māori experienced a similar incidence of GCA to New Zealand Europeans (<a href=""https://pubmed.ncbi.nlm.nih.gov/35663155/"" target=""_blank"">Nagarajah et al. Rheumatol Adv Pract. 2022;6:rkac040</a>), however the Committee considered that outcome data comparing Māori to other populations was lacking. The Committee noted that nearly all cases of GCA are treated with high doses of prednisone for at least a year, and around 25% are still receiving treatment after five years (<a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9723338/"" target=""_blank"">Lyne et al. Front Med (Lausanne). 2022;9:1057917</a>). The Committee agreed with the Rheumatology Advisory Committee, who, in <a href=""https://pharmac.govt.nz/assets/2023-03-28-Rheumatology-Advisory-Committee-meeting-record.pdf"" target=""_blank"">March 2023,</a> considered that most of the comorbidities associated with corticosteroid use inequitably affect Māori, and thus considered that this should be taken into account when assessing alternative therapies such as tocilizumab. The Committee noted that GCA is not included within Hauora Arotahi (Māori health area of focus) in Te Whaioranga, Pharmac’s Māori Responsiveness Strategy.</p><h2><em>Impact on Pacific peoples, disabled people, tāngata whaikaha Māori, and people who have been underserved by the health system</em></h2><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the possible impact of funding tocilizumab for the treatment of GCA on Pacific peoples, disabled people, tāngata whaikaha Māori, and people who have been underserved by the health system. The Committee was not aware of any groups experiencing health inequities disproportionately affected by GCA.</p><h2><em>Background</em></h2><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that intravenous tocilizumab is currently <a href=""https://schedule.pharmac.govt.nz/2023/07/01/SA2159.pdf"" target=""_blank"">funded</a> in New Zealand for the treatment of cytokine release syndrome, rheumatoid arthritis, juvenile idiopathic arthritis (systemic and polyarticular), adult-onset Still’s disease, idiopathic multicentric Castleman’s disease, and moderate to severe COVID-19.</p><p><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the Rheumatology Advisory Committee reviewed an application for the funding of tocilizumab for the treatment of polymyalgia rheumatica (PMR) in <a href=""https://pharmac.govt.nz/assets/2023-03-28-Rheumatology-Advisory-Committee-meeting-record.pdf"" target=""_blank"">March 2023</a>, and recommended the application be deferred pending the availability of further evidence to define the intended population to treat, treatment duration, and the appropriate timing of when to start treatment. When making this recommendation, the Rheumatology Advisory Committee considered there was a high need to fund agents such as tocilizumab for GCA.</p><p><em>Health need</em></p><p><span style=""color: black;"">1.5.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that GCA (previously known as Horton’s disease or temporal arteritis) is a rare type of autoimmune chronic systemic vasculitis (inflammation of the blood vessels) that typically affects the cranial arteries (especially the temporal and ophthalmic arteries), and less commonly the branches of the aorta (<a href=""https://pubmed.ncbi.nlm.nih.gov/22285588/"" target=""_blank"">Borchers et al. Automimmun Rev. 2012;11:544-54</a>). The Committee noted that GCA is characterised by granulomatous inflammation of the three-layered vessel wall that results in vaso-occlusion, wall dissection, and aneurysm formation (<a href=""https://pubmed.ncbi.nlm.nih.gov/36656970/"" target=""_blank"">Weyand et al. Circ Res. 2023;132:238-50)</a>. The Committee noted that <span style=""color: black;"">although the exact cause of\xa0GCA is unknown, the </span>pathophysiology involves a multi-step process with a pronounced acute phase response involving pro-inflammatory cytokines, in particular IL-6 which is an important mediator of inflammation <a href=""https://pubmed.ncbi.nlm.nih.gov/22285588/"" target=""_blank"">(Borchers et al. Autoimmun Rev. 2012;11:544-54</a>, <a href=""https://pubmed.ncbi.nlm.nih.gov/26239828/"" target=""_blank"">Steel et al. Drugs Aging. 2015;32:591-9</a>).</p><p><span style=""color: black;"">1.6.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that PMR is closely linked to GCA, occurring in approximately 40-60% of people with GCA, although the precise nature of the relationship between GCA and PMR is not completely understood (<a href=""https://bpac.org.nz/bpj/2013/june/docs/BPJ53pages16-23.pdf"" target=""_blank"">bpac<sup>nz</sup>. 2013;53:17-23</a>). The Committee note that conversely, GCA is found in approximately 15-20% of people with PMR (<a href=""https://pubmed.ncbi.nlm.nih.gov/33706808/"" target=""_blank"">Li et al. Arthritis Res Ther. 2021;23:82</a>).</p><p><span style=""color: black;"">1.7.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the incidence of GCA increases with age, most commonly affecting people aged over 50 years, and is two to three times more common in females than males (<a href=""https://pubmed.ncbi.nlm.nih.gov/22285588/"" target=""_blank"">Borchers et al. Autoimmun Rev. 2012;11:544-54</a>, <a href=""https://pubmed.ncbi.nlm.nih.gov/26239828/"" target=""_blank"">Steel et al. Drugs Aging. 2015;32:591-9</a>).The Committee noted that from the literature, the highest reported rates of GCA are in northern Europe (especially in people of Scandinavian descent), although it can also affect other groups (<a href=""https://pubmed.ncbi.nlm.nih.gov/19790127/"" target=""_blank"">Gonzalez-Gay et al. Arthritis Rheum. 2009;6:1454)</a>. The Committee noted that the estimated incidence of GCA in New Zealand is 12.73 per 100,000 New Zealanders (<a href=""https://pubmed.ncbi.nlm.nih.gov/21475359/"" target=""_blank"">Abdul-Rahman et al. N Z Med J. 2011;124:44-52</a>), around 270 people are expected to be diagnosed with GCA each year in New Zealand.</p><p><span style=""color: black;"">1.8.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that Māori experience similar incidence of GCA to New Zealand Europeans (<a href=""https://pubmed.ncbi.nlm.nih.gov/35663155/"" target=""_blank"">Nagarajah et al. Rheumatol Adv Pract. 2022;6:rkac040</a>), however considered that outcome data comparing Māori to other populations is lacking. The Committee noted that nearly all cases of GCA are treated with high doses of prednisone for at least a year, and around 25% are still receiving treatment after five years (<a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9723338/"" target=""_blank"">Lyne et al. Front Med (Lausanne). 2022;9:1057917</a>). The Committee considered that steroid use differs between ophthalmology and rheumatology with visual problems caused by GCA requiring higher dose steroids The Committee agreed with the comments from the Rheumatology Advisory Committee in <a href=""https://pharmac.govt.nz/assets/2023-03-28-Rheumatology-Advisory-Committee-meeting-record.pdf"" target=""_blank"">March 2023</a>, that most of the comorbidities associated corticosteroid use inequitably affect Māori, and thus considered that this should be accounted for when assessing alternative therapies such as tocilizumab.</p><p><span style=""color: black;"">1.9.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the onset of symptoms in GCA tend to be subacute, but abrupt presentations over a few days can occur. The Committee noted that temporal headache is the most frequent symptom of GCA and will be present in approximately 75% of cases. The Committee noted that systemic features, including low-grade fever, anorexia, and fatigue are present in approximately half of those affected (<a href=""https://bpac.org.nz/bpj/2013/june/docs/BPJ53pages16-23.pdf"" target=""_blank"">bpac<sup>nz</sup>. 2013;53:17-23</a>). The Committee noted that if undetected, GCA can have catastrophic sequelae, such as irreversible visual loss, stroke, and aortic aneurysm development. The Committee noted that loss of vision can be permanent, and large-vessel stenosis, and with it an increased risk of stroke, occurs in 10-15% of people (<a href=""https://pubmed.ncbi.nlm.nih.gov/23253927/"" target=""_blank"">Kermani et al.. Ann Rheum Dis. 2013;72:1989-94</a>).</p><p><span style=""color: black;"">1.10.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that current treatment of GCA aims to dampen the acute inflammatory process, thereby preventing ischemic complications, prevent disease relapses using the lowest effective dose (if any) of corticosteroids, and prevent long-term vascular damage (ie aneurysm, vascular rupture, and stenosis) (<a href=""https://pubmed.ncbi.nlm.nih.gov/36344353/"" target=""_blank"">Farina et al. Eur J Intern Med. 2023;107:17-26</a>).</p><p><span style=""color: black;"">1.11.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that the European Alliance of Associations for Rheumatology (EULAR) and British Society for Rheumatology (BSR) guidelines recommend starting treatment with high-dose corticosteroid therapy for a minimum of four weeks, gradually tapering the course, and adding methotrexate if flares occur.</p><p><span style=""color: black;"">1.12.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that GCA can impact on the whānau of individuals with GCA due to the effect of the disease on friendships and relationships, the affected individual’s ability to work, support children, and take part in recreational activities whilst symptomatic. The Committee considered that the chronic nature of GCA, prolonged treatment with steroids, and serious morbidity described all contribute to the currently high unmet health need of the condition.</p><p><em>Health benefit</em></p><p><span style=""color: black;"">1.13.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted tocilizumab is a humanised monoclonal antibody that targets the interleukin-6 (IL-6) receptor which is involved in immunological and inflammatory reactions. The Committee noted that only the subcutaneous formulation of tocilizumab is <a href=""https://medsafe.govt.nz/profs/Datasheet/a/Actemrainf.pdf"" target=""_blank"">approved by Medsafe</a> for the treatment of GCA in adults. The Committee noted that the recommended dose of tocilizumab for adults with GCA is 162 mg once weekly as a subcutaneous injection, in combination with a tapering course of corticosteroids. The Committee noted that tocilizumab may be used alone following discontinuation of corticosteroids. The Committee noted that tocilizumab is currently recommended for the treatment of GCA in <a href=""https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2019-03/files/tocilizumab-GCA-psd-march-2019.pdf"" target=""_blank"">Australia,</a> <a href=""https://www.cadth.ca/sites/default/files/cdr/complete/SR0534_Actemra_GCA_complete_Mar-27-18.pdf"" target=""_blank"">Canada</a>, <a href=""https://www.scottishmedicines.org.uk/media/3693/tocilizumab-roactemra-final-august-2018-for-website.pdf"" target=""_blank"">Scotland</a>, and <a href=""https://www.nice.org.uk/guidance/TA518/chapter/1-Recommendations"" target=""_blank"">England/Wales</a>. The Committee noted that tocilizumab does not treat GCA but rather dampens the inflammatory process.</p><p><span style=""color: black;"">1.14.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that the applicant suggests that the current treatment algorithm (corticosteroid monotherapy) is altered to include tocilizumab for both new-onset (first line), and flare management (second line) treatment of GCA. The Committee considered agreed with the applicants view of the treatment algorithm. The Committee considered that patients not responding to current treatment would receive higher doses, and many patients would also receive methotrexate.</p><p><span style=""color: black;"">1.15.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Giant-Cell Arteritis Actemra (GiACTA) trial provided the primary evidence for tocilizumab for the treatment of GCA (<a href=""https://pubmed.ncbi.nlm.nih.gov/28745999/"" target=""_blank"">Stone et al. 2017. N Engl J Med. 2017;377:317-28</a>, <a href=""https://pubmed.ncbi.nlm.nih.gov/34718434/"" target=""_blank"">Stone et al. Rheumatology (Oxford). 2022;61:2915-22</a>, <a href=""https://pubmed.ncbi.nlm.nih.gov/30915462/"" target=""_blank"">Adler et al. Rheumatology (Oxford).2019;58:1639-43</a>, <a href=""https://pubmed.ncbi.nlm.nih.gov/30786937/"" target=""_blank"">Strand et al. Arthritis Res Ther. 2019;21:64</a>). The Committee noted that the trial was a phase III, randomised, double-blind, placebo-controlled, multicentre study of adult patients with either new onset or relapsing GCA (<em>N</em>=251) who were randomised in a 1:1:2:1 ratio to receive the following treatments for 52 weeks:</p><p class=""ql-indent-1""><span style=""font-size: 11pt; font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 11pt;"">Placebo subcutaneously (SC) weekly (QW) + 26-week prednisone taper regimen (PBO + 26 week; </span><em style=""font-size: 11pt;"">n=</em><span style=""font-size: 11pt;"">50) </span></p><p class=""ql-indent-1""><span style=""font-size: 11pt; font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 11pt;"">Placebo SC QW + 52-week prednisone taper regimen (PBO + 52 week; </span><em style=""font-size: 11pt;"">n=</em><span style=""font-size: 11pt;"">50) </span></p><p class=""ql-indent-1""><span style=""font-size: 11pt; font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 11pt;"">162 mg tocilizumab SC QW + 26-week prednisone taper regimen (tocilizumab QW; </span><em style=""font-size: 11pt;"">n</em><span style=""font-size: 11pt;"">=100) </span></p><p class=""ql-indent-1""><span style=""font-size: 11pt; font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 11pt;"">162 mg tocilizumab SC every other week (Q2W) + 26-week prednisone taper regimen (tocilizumab Q2W; </span><em style=""font-size: 11pt;"">n</em><span style=""font-size: 11pt;"">=50)</span></p><p class=""ql-indent-2"">1.15.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that after the 52-week double-blind treatment period (Part 1), all patients who had completed Part 1 of the study were eligible to enter the 104-week open-label extension of the study.</p><p class=""ql-indent-2"">1.15.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that the primary endpoint was proportion of patients in sustained remission from weeks 12 to 52 with adherence to a standardised 26-week (short course) corticosteroid taper compared with a 26-week corticosteroid taper given alone in the placebo group. The Committee noted that sustained remission at week 52 was 56% tocilizumab weekly (QW) and in 53% tocilizumab every two weeks (Q2W), 14% placebo group with 26-week prednisone taper and 18% in the placebo group with 52-week prednisone taper (<em>P</em>&lt;0.001 for the comparisons of either active treatment with placebo).</p><p class=""ql-indent-2"">1.15.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted the following results from secondary endpoints:</p><p class=""ql-indent-3""><span style=""font-size: 11pt; font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 11pt;"">Less prednisone used in the tocilizumab groups than placebo over 52 weeks.</span></p><p class=""ql-indent-3""><span style=""font-size: 11pt; font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 11pt;"">Fewer flares in the tocilizumab groups than placebo over 52 weeks, and over the 3-year extension period.</span></p><p class=""ql-indent-3""><span style=""font-size: 11pt; font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 11pt;"">In patients with new-onset and relapsing disease, the median time to first flare in the tocilizumab QW group was 577 and 575\u2009days, respectively, vs 479 and 428\u2009days with tocilizumab Q2W and 179 and 224\u2009days with placebo.</span></p><p class=""ql-indent-2"">1.15.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that there was a mean increase of the 36-item short form survey (SF-36) quality of life measure in the groups that received tocilizumab, and a decreased SF-36 in groups that received placebo. The Committee noted that the improved quality of life was greater in the group that receive tocilizumab weekly than in the group that received tocilizumab every two weeks.</p><p><span style=""color: black;"">1.16.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that tocilizumab was a reasonably safe treatment for GCA, noting that no deaths occurred in the first 52 weeks of the GiACTA trial, and that withdrawal from the trial due to adverse events occurred in 6% of the patients in each tocilizumab group, 4% placebo with 26-week taper, and none in the other placebo group.</p><p><span style=""color: black;"">1.17.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted the results of a two-year open-label extension phase of the GiACTA trial and a previous phase II trial. The Committee considered these trials demonstrated that the relapse rate following abrupt discontinuation of tocilizumab is high, noting that more than 50% of those achieving remission on tocilizumab later relapsed once treatment was stopped (<a href=""https://pubmed.ncbi.nlm.nih.gov/30915462/"" target=""_blank"">Adler et al. Rheumatology (Oxford).2019;58:1639-43</a>, <a href=""https://www.sciencedirect.com/science/article/abs/pii/S2665991321000382"" target=""_blank"">Stone et al. Lancet Rheumatol. 2021;3:e328-36</a>). The Committee considered that there is currently insufficient evidence to define optimal duration of treatment and dosing schedule beyond 12 months for tocilizumab for GCA, but the above evidence suggested that treatment may need to be continued for longer than 12 months. The Committee considered that for people in remission after 12 months of treatment, a dose reduction of tocilizumab may be appropriate. However, the Committee noted that those from the extension study who received weekly (QW) tocilizumab experienced less flares, and improved quality of life in comparison to those who received tocilizumab every 2 weeks.\xa0(<a href=""https://pubmed.ncbi.nlm.nih.gov/36377586/"" target=""_blank"">Calderon-Goerke et al, Clin Exp Rheumatol. 2023;41:829-36,</a> <a href=""https://ard.bmj.com/content/80/Suppl_1/655.1"" target=""_blank"">Rakholiya et al. An Rheum Dis. 2021;80:655</a>, <a href=""https://pubmed.ncbi.nlm.nih.gov/36774660/"" target=""_blank"">Tomelleri et al. Semin Arthritis Rheum. 2023;59:152-74).</a></p><p><span style=""color: black;"">1.18.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that there are differing recommendations on when to start tocilizumab for GCA; the <a href=""https://pubmed.ncbi.nlm.nih.gov/34235884/"" target=""_blank"">American College of Rheumatology/Vasculitis Foundation (ACR/VF)</a> recommended tocilizumab for all patients with newly diagnosed GCA, and the <a href=""https://ard.bmj.com/content/79/1/19"" target=""_blank"">European Alliance of Associations for Rheumatology (EULAR</a>) recommended tocilizumab in those with, or at risk of, corticosteroid-related adverse events or in patients who have relapsing disease. The Committee considered that New Zealand practice would likely align with the EULAR recommendations.</p><p><span style=""color: black;"">1.19.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that the evidence for tocilizumab in GCA was of good quality due to the GiACTA trial’s methodology and duration of the study.\xa0</p><p><span style=""color: black;"">1.20.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that there is currently no data available on the use of intravenous tocilizumab for the treatment of GCA, although considered that it is expected that intravenous and subcutaneous tocilizumab are likely to provide the same or similar efficacy for this condition.</p><p><em>Suitability</em></p><p><span style=""color: black;"">1.21.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that tocilizumab subcutaneous injections are available as pre-filled syringes and are self-administered. The Committee considered that individuals would require training for self-administration. The Committee noted that as per the <a href=""https://medsafe.govt.nz/profs/Datasheet/a/Actemrainf.pdf"" target=""_blank"">Medsafe datasheet</a>, the syringes require refrigeration, and once removed from the refrigerator can be stored up to 14 days at or below 30°C.</p><p><span style=""color: black;"">1.22.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered the advantages of the availability of a subcutaneous tocilizumab formulation for the treatment of GC. The Committee considered that a subcutaneous treatment would ease pressure on hospital and community infusion services, and allow people to self-administer, or have a caregiver help to administer at home which would improve access for people located rurally and/or unable to travel to infusion centre. Members noted that there would likely still be a health system and personal cost for those people who require or prefer health-professional administration of subcutaneous treatment.</p><p><em>Cost and savings</em></p><p><span style=""color: black;"">1.23.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that treatment of GCA with tocilizumab may reduce the cost of treating disease flares, including the number of healthcare practitioner visits. The Committee considered that treatment with high-dose long-term corticosteroids increases the risk of fractures, obesity, diabetes, cardiovascular disease, and serious infections; therefore, treatment that reduces the risk of these adverse effects is likely to result in health benefits and savings to the health sector.</p><p><span style=""color: black;"">1.24.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that patient number and uptake estimates appeared reasonable.<em> </em></p><p><span style=""color: black;"">1.25.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>\xa0The Committee considered it is difficult to estimate the cost of tocilizumab treatment due to the uncertainty regarding treatment duration. The Committee considered it likely that at least 50% of people would receive treatment beyond 12 months. The Committee considered there may be a cost for radiology services to assess blood vessel inflammatory response to treatment, and that there may be increased referrals to rheumatology services to access diagnosis and subsequent treatment.</p><p><em>Funding criteria</em></p><p><span style=""color: black;"">1.26.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that future funding criteria would require a definitive diagnosis of GCA. The Committee considered that people may need to have completed a trial of methotrexate (3-6 months) before accessing tocilizumab. The Committee also considered that there should be a restriction surrounding corticosteroid dose tapering, suggesting that less than 10 mg was ineffective, despite a maximum appropriate dose of methotrexate.</p><p><em>Summary for assessment</em></p><p><span style=""color: black;"">1.27.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""color: black;"">The Advisory Committee considered that the table below summarises its interpretation of the most appropriate PICO (population, intervention, comparator, outcomes) information for tocilizumab if it were to be funded in New Zealand for [the indication]. This PICO captures key clinical aspects of the proposal and may be used to frame any future economic assessment by Pharmac staff. This PICO is based on the Advisory Committee’s assessment at this time and may differ from that requested by the applicant. The PICO may change based on new information, additional clinical advice, or further analysis by Pharmac staff.</span></p><p><span style=""color: black;"">1.28.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""color: black;"">The Advisory Committee noted that elements of in the</span><em style=""color: black;""> </em><span style=""color: black;"">PICO (population, intervention, comparator, outcomes) for this application is unclear/uncertain at this time. The PICO may develop based on new information, additional clinical advice, or further analysis by Pharmac staff.</span></p><p><span style=""color: black;"">\ufeff</span><img src=""/apptracker/servlet/rtaImage?eid=a0POZ000004CpcO&amp;feoid=00N2P000000YsIc&amp;refid=0EMOZ000000Tqxh"" alt=""image.png""></img></p>', 'Status_History__c': 'a13OZ000003INe6YAG'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Nov 2023', 'fs': 'Nov 2023', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000004CpcP2AS'}, 'Id': 'a0POZ000004CpcP2AS', 'Event_Date__c': '2023-11-04', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Nov 2023', 'Status_History__c': 'a13OZ000005mq6QYAQ'}, 'change': None}]",May 2023,False,True
2,"<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/"" rel=""nofollow"">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>
<p>&nbsp;</p>
<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>
<ul>
<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>
<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>
<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>
</ul>
<p>&nbsp;</p>
<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",2,Under Assessment,False,,,False,False
3,"<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmac’s decision-making process.</p>
<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>
<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>
<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",3,Options Compared,False,,,False,False
4,"<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",4,Under Consultation,False,,,False,False
5,"<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",5,Reviewing Consultation Feedback,False,,,False,False
6,"<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>
<p>We consider and assess all funding decisions using the&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc"" rel=""nofollow"">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>
<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>
<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>
<p>&nbsp;</p>",6,Decision,True,,,False,False
